Abstract
Retigabine is a new anticonvulsant in clinical development, which activates neuronal M-current by opening voltage-gated potassium channels (KCNQ2/3 and KCNQ3/5). Retigabine had demonstrated potent anticonvulsant activity in various animal models of epileptic seizures including partial and generalized seizure models as well as status epilepticus model. Up to date, three pivotal clinical studies had been completed in patients with partial seizures as an adjunctive therapy. These studies showed that retigabine doses of 600-1200 mg/day (200-400 mg three times daily) were associated with significant reduction in seizure frequency when compared with placebo. Retigabine was generally well tolerated and most commonly reported adverse events were CNS-related (i.e. dizziness and confusion) in clinical trials. This article reviewed retigabines primary mechanism of action, pharmacokinetics, and preclinical data as well as its efficacy and safety in patients with epilepsy.
Current Drug Therapy
Title: Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?
Volume: 5 Issue: 1
Author(s): Steve S. Chung
Affiliation:
Abstract: Retigabine is a new anticonvulsant in clinical development, which activates neuronal M-current by opening voltage-gated potassium channels (KCNQ2/3 and KCNQ3/5). Retigabine had demonstrated potent anticonvulsant activity in various animal models of epileptic seizures including partial and generalized seizure models as well as status epilepticus model. Up to date, three pivotal clinical studies had been completed in patients with partial seizures as an adjunctive therapy. These studies showed that retigabine doses of 600-1200 mg/day (200-400 mg three times daily) were associated with significant reduction in seizure frequency when compared with placebo. Retigabine was generally well tolerated and most commonly reported adverse events were CNS-related (i.e. dizziness and confusion) in clinical trials. This article reviewed retigabines primary mechanism of action, pharmacokinetics, and preclinical data as well as its efficacy and safety in patients with epilepsy.
Export Options
About this article
Cite this article as:
Chung S. Steve, Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010010
DOI https://dx.doi.org/10.2174/1574885511005010010 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) The Muscular Dystrophies Associated with Central Nervous System Lesions: A Brief Review from a Standpoint of the Localization and Function of Causative Genes
Current Pediatric Reviews The Interaction of DNA-Binding Ligands with Trinucleotide-Repeat DNA: Implications for Therapy and Diagnosis of Neurological Disorders
Current Topics in Medicinal Chemistry The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential
Current Neuropharmacology Assessment of Possible Drug Interactions in Patients with Psoriasis and Associated Comorbid Medical Conditions: An Observational Study
Reviews on Recent Clinical Trials Filtering Disturbances in Schizophrenic Patients. Gating of Auditory Evoked Potentials and Prepulse Inhibition of the Acoustic Startle Response Compared. Emphasis on the Role of Dopamine
Current Neuropharmacology VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Postpartum Psychiatric Disorders: What Do We Know And Where Do We Go?
Current Psychiatry Reviews Role of Physical Exercise as Complementary Treatment for Epilepsy and other Brain Disorders
Current Pharmaceutical Design Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets Recent Developments of the PET Imaging Agents for Metabotropic Glutamate Receptor Subtype 5
Current Topics in Medicinal Chemistry Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Opinion Paper: Post-surgical Delirium, Consciousness, and Therapy
Recent Patents on CNS Drug Discovery (Discontinued) AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders
Current Topics in Medicinal Chemistry The Roles of Metabotropic Glutamate Receptors in Seizures and Epilepsy
Current Drug Targets - CNS & Neurological Disorders